AdaptHealth price target lowered to $17 from $20 at Truist

Truist analyst David MacDonald lowered the firm’s price target on AdaptHealth to $17 from $20 but keeps a Buy rating on the shares as part of a broader research note on Health Care names. The firm remains bullish across much of Health Care Services given attractive core demand, the ongoing shift to value, reasonable valuations and impacts on the system over the past few years that have further tipped the playing field in favor of scaled and high quality providers, even though it still sees some macro challenges around a potential recession, available labor, and inflation.